Bone morphogenetic protein 4 ameliorates bleomycin-induced pulmonary fibrosis in mice by repressing NLRP3 inflammasome activation and epithelial-mesenchymal transition

Xin Xu(Shanghai University of Sport), Wenju Lu(Guangzhou Experimental Station), Fei Huang(First Affiliated Hospital of Guangzhou Medical University), Ruijuan Guan(First Affiliated Hospital of Guangzhou Medical University), Wei Liu(Second People’s Hospital of Yibin), You Zhou(Hebei University), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Xiao Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Chen(First Affiliated Hospital of Guangzhou Medical University), Jingpei Li(Guangzhou Medical University), Hui‐Hui Wu, Jingyi Xu(Jining Medical University), Yunhan Zou(First Affiliated Hospital of Guangzhou Medical University), Weiguo Kong(First Affiliated Hospital of Guangzhou Medical University), Yijun Shen(First Affiliated Hospital of Guangzhou Medical University)
Journal of Thoracic Disease
August 1, 2024
10.21037/jtd-23-1947
Cited by 4

Related Papers

Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization
|Journal of Neuroinflammation|2020|609
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
|Journal of Clinical Oncology|2017|358
Choice of Surgical Procedure for Patients With Non–Small-Cell Lung Cancer ≤ 1 cm or &gt; 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study
|Journal of Clinical Oncology|2016|245